Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification
- Journal
- Molecular Pharmaceutics
In The Last Decade
doi.org/10.1021/mp034006h →Countries where authors are citing Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification
This map shows the geographic impact of Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification more than expected).
Fields of papers citing Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification
This network shows the impact of Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification.
About Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification
This paper, published in 2003, received 696 indexed citations . Written by Chandrasekharan Ramachandran, Marival Bermejo, Hans Lennernäs, Ajaz Hussain, Hans E. Junginger, Salomon Stavchansky, Kamal K. Midha, Vinod P. Shah and Gordon L. Amidon covering the research area of Oncology, Analytical Chemistry and Pharmaceutical Science. It is primarily cited by scholars working on Pharmaceutical Science (370 citations), Materials Chemistry (136 citations) and Analytical Chemistry (127 citations). Published in Molecular Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1021/mp034006h.